文献速递免疫规划

四价脑膜炎球菌白喉类毒素结合疫苗加强剂后4年杀菌抗体持久性

Persistence of bactericidal antibodies 4 years after a booster dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D).
PubMed 文献 · Vaccine · 2019-01-19

研究评估110名青少年在接种MenACWY-D加强剂4年后的血清杀菌抗体持久性。89.9-98.2%的参与者维持hSBA滴度≥1:4的保护水平,81.7-97.2%达到更严格的≥1:8阈值。结果支持ACIP关于16岁加强接种的推荐。

要点

  • MenACWY-D加强剂后4年,89.9-98.2%参与者维持hSBA≥1:4保护滴度
  • 81.7-97.2%参与者达到更严格的hSBA≥1:8阈值
  • 结果支持ACIP推荐16岁加强接种以覆盖高风险期

核心结论

  • MenACWY-D加强剂后4年,大多数青少年维持与侵袭性脑膜炎球菌病保护相关的hSBA滴度。

研究设计与样本

  • 2期研究样本中110名参与者,在接种MenACWY-D加强剂4年后采用人补体血清杀菌试验(hSBA)评估抗体持久性。

主要发现

  • 89.9-98.2%的参与者维持hSBA滴度≥1:4。
  • 81.7-97.2%的参与者hSBA滴度≥1:8。

关键数值与推荐

  • hSBA滴度≥1:4为与侵袭性脑膜炎球菌病保护相关的阈值。
  • hSBA滴度≥1:8为更严格的阈值。

临床怎么用

  • 支持ACIP关于MenACWY加强疫苗接种的推荐,以在青少年和年轻成人IMD风险增高期间提供保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

One dose of quadrivalent meningococcal conjugate vaccine (MenACWY) was first recommended for US adolescents (ages 11-12 years) in 2005 to protect against invasive meningococcal disease (IMD). In 2010, after evidence emerged about waning protection within 5 years after MenACWY vaccination, the US Advisory Committee on Immunization Practices (ACIP) recommended a MenACWY booster at age 16 years. We used a serum bactericidal assay with human complement (hSBA) to evaluate antibody persistence after a MenACWY-D booster in a sample of 110 participants who received the booster 4 years earlier in a phase 2 study. High proportions (89.9-98.2%) of participants maintained hSBA titers (≥1:4) associated with protection against IMD; a majority (81.7-97.2%) also had hSBA titers ≥1:8, a more conservative threshold. These findings support ACIP recommendations regarding MenACWY booster vaccination, which are aimed at protecting adolescents and young adults throughout the period in which they are at increased risk of IMD.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Robertson CA, Hedrick J, Bassily E, et al. Persistence of bactericidal antibodies 4 years after a booster dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D). Vaccine. 2019. PMID: 30670301. doi:10.1016/j.vaccine.2019.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。